Sionna Therapeutics

SION

Market cap $1.89B

Sionna Therapeutics, Inc. (SION) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sionna Therapeutics' Chief Legal Officer sold 10,250 shares for over $400k on Dec. 5, 2025. The company's stock has performed strongly in its first year on the market.

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44th Annual J.P.

33,356 shares sold for a transaction value of $1,486,009.80 on Dec. 24, 2025. Reducing total indirect ownership to 3,561,655 shares.

Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025, at 8:30 a.m.

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington October 22-25.

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta ® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF.